A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers
Latest Information Update: 24 Dec 2024
Price :
$35 *
At a glance
- Drugs Cemiplimab (Primary) ; Pegenzileukin (Primary) ; Tebentafusp (Primary)
- Indications Carcinoma; Malignant melanoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 19 Dec 2024 Status changed from active, no longer recruiting to discontinued.
- 20 Feb 2024 Planned End Date changed from 27 Jan 2025 to 11 Feb 2025.
- 29 Aug 2023 Planned End Date changed from 5 Jun 2026 to 27 Jan 2025.